For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Article by leading independent Australian biotech analysts in the weekly Bioshares magazine on 8 April 2016 "Pharmaxis - NASH Continues to Attract Major Drug Development Deals"Read full media release - pdf
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to report progress from its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Overnight Synairgen announced data generated in an in vitro model of IPF using lung cells from IPF patients, developed in collaboration with scientists at the University of Southampton. The data shows that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, are able to reduce cross-linking of collagen fibres essential for the stabilization of fibrotic tissue.Read full media release - pdf
Science Meets Business Top 25 R&D Companies
Pharmaxis ranks high on the list of R&D Top 25 for 2016.
Science Meets Business - Top 25 insights
Commentary from the Pharmaxis CEO and others from the Top 25 R&D spin-off companies on